about
Structural mass spectrometry of tissue extracts to distinguish cancerous and non-cancerous breast diseases.Oligometastatic breast cancer: a shift from palliative to potentially curative treatment?Implication of duration of clinical presentation on tumor progression and short-term recurrence in patients with early breast cancerTransferrin-bound proteins as potential biomarkers for advanced breast cancer patients.Virtual High-Throughput Screening To Identify Novel Activin Antagonists.Discovery of New Acid Ceramidase-Targeted Acyclic 5-Alkynyl and 5-Heteroaryl Uracil Nucleosides.Doxorubicin-Hyaluronan Conjugated Super-Paramagnetic Iron Oxide Nanoparticles (DOX-HA-SPION) Enhanced Cytoplasmic Uptake of Doxorubicin and Modulated Apoptosis, IL-6 Release and NF-kappaB Activity in Human MDA-MB-231 Breast Cancer Cells.Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis: A Case-control Study With Comparison to Medically Treated PatientsTrastuzumab-grafted PAMAM dendrimers for the selective delivery of anticancer drugs to HER2-positive breast cancer.In Vivo Bioluminescence Tomography for Monitoring Breast Tumor Growth and Metastatic Spreading: Comparative Study and Mathematical Modeling.A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy.Advances in the approach to novel drug clinical development for breast cancer.Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study.Palliation and breast cancer.Mammalian sterile 20-like kinase 1 expression and its prognostic significance in patients with breast cancer.MAPK, NFκB, and VEGF signaling pathways regulate breast cancer liver metastasis.Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast CancerCure in metastatic breast cancer
P2860
Q34282970-AC2A9149-763C-4105-A622-722C077CC9BAQ35164247-04F14F27-588B-4621-8544-AA50DE753B03Q35802796-A45D854B-591E-4488-AB64-D037D08DA1A4Q36250711-43B743CB-3EFD-4C0C-8AEB-B0B56DBBC6A3Q36256670-458D5B4C-4442-4553-96D6-B5C569119532Q36281044-E10142AE-945F-4245-9047-E07D05D0B150Q36377493-ED1E162D-C03D-444C-A6BF-B79F8C0335A6Q36757904-3C523572-7710-4292-9B08-119F6205C616Q36774169-C7FABC12-0F39-4EEB-9002-D07B64086FE6Q37394265-039C1C76-1D6C-4DB9-80C3-D8017C61C99EQ37699360-5F3715B4-FD27-4151-8AA2-0C0EFC304BCFQ38206546-2355C462-6E51-4519-AC29-178CFAD1BBB9Q39008777-8D42417B-9964-4506-8459-83A22539F794Q39093218-808AF741-7461-46C6-B907-5F18ACDF033EQ47147401-53386086-3151-4FFA-91D2-730B3C164CFEQ47160810-61B85F30-F4C5-4C6C-9DDF-1A22B5BDCD15Q47714743-1949067A-2D4F-4137-9FD8-03BAC63A7A2BQ57115279-C9A8C3FB-BE68-463C-8F9D-C1AA3D253DBF
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Time for more optimism in metastatic breast cancer?
@ast
Time for more optimism in metastatic breast cancer?
@en
type
label
Time for more optimism in metastatic breast cancer?
@ast
Time for more optimism in metastatic breast cancer?
@en
prefLabel
Time for more optimism in metastatic breast cancer?
@ast
Time for more optimism in metastatic breast cancer?
@en
P1476
Time for more optimism in metastatic breast cancer?
@en
P2093
Olivia Pagani
P304
P356
10.1016/J.CTRV.2013.09.015
P577
2013-10-01T00:00:00Z